AUG 07, 2018 11:00 PM PDT

Can a Myeloid Marker Be Helpful in B-cell Neoplasm Diagnostic Testing?

Diagnostic testing for hematologic and other cancers has been a traditional method of evaluating, diagnosing, and providing prognostic information to providers choosing treatment and options for oncology patients.  Molecular diagnostics, in particular, have jumped to the forefront of diagnostic testing to provide not only a diagnosis, but to also evaluate the biomarkers present in particular groups of cells; biomarker identification predicts disease behavior, helps in selection of therapeutic treatment targets and options, assists in stratification of disease, and provides a personalized medicine approach. 

Immunophenotyping has become an invaluable diagnostic tool used by clinicians and hematopathologists to fit cancers into appropriate subgroups based on the biomarkers present on tumor involved cell lines. 

There are a multitude of B-cell neoplasms including multiple myeloma, chronic lymphocytic leukemia, small lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, Burkitt’s lymphoma, Mantle cell lymphoma, and others.  In these cases, because they are lymphoid in origin, it is unexpected to find myeloid markers, however, researchers at Stanford and Oregon Health Sciences in Portland found that CD13, a myeloid marker, is expressed in a subset of lymphomas which can be helpful in differentiating between B-cell neoplasms in the clinical setting.

The group published their findings in the International Journal of Laboratory Hematology, which outlined their analysis of 286 mature B-cell neoplasms after immunophenotyping was completed.  CD13 expression was found in cases of lymphoplasmacytic lymphoma (LPL) (61.5% of cases) and FMC7-positive chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (37% of cases).  Notably, there were no cases of follicular lymphoma that expressed CD13. 

The group concluded that CD13 expression is usually present in LPL and FMC7-positive CLL or SLL and is not found in FL.  Historically, CD13 has not been used to characterize B-cell neoplasm subtypes but could be a useful diagnostic means to aid in neoplasm subtyping and furthering B-cell neoplasm therapeutic targeting.

Sources: International Journal of Laboratory Hematology, Archives of Pathology & Laboratory Medicine, Clinics in Oncology , Modern Pathology 

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
OCT 21, 2019
Cancer
OCT 21, 2019
An Ointment to Stop Skin Cancer Growth
Russian scientists are developing an ointment to undermine the growth of skin cancer, according to a review recently published in Molecules. One in three c...
OCT 21, 2019
Cancer
OCT 21, 2019
New anticancer agent discovered
A new study published in the Journal of the American Chemical Society showcases research from Purdue University on the development of an anticancer agent t...
OCT 21, 2019
Drug Discovery & Development
OCT 21, 2019
Aspirin Usage Improves Liver Function After Embolization Treatment
Aspirin usage has been under scrutiny in recent research. But now, studies are bringing aspirin therapy in renewed light with its association in improving ...
OCT 21, 2019
Drug Discovery & Development
OCT 21, 2019
Unprecedented Therapeutic Found Effective for Blood Cancer
According to the findings of a clinical trial, scientists at Mt. Sinai have found a new therapeutic effective for patients with a particular type of b...
OCT 21, 2019
Cell & Molecular Biology
OCT 21, 2019
Dysfunctional Mitochondria Cause Telomere Damage
"I like to call it 'the Chernobyl effect' -- you've turned the reactor on and now you can't turn it off," said senior author Bennett Van Houten, Ph.D....
OCT 21, 2019
Cancer
OCT 21, 2019
Not worth the risk: e-cigs and lung inflammation
E-cigarette use is on the rise and according to new research published in the journal Cancer Prevention Research, even short-term usage of e-cigs can be a ...
Loading Comments...